Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab plus paclitaxel versus placebo plus paclitaxel in first-line HER2-negative metastatic breast cancer
2011-005335-97Phase 3Terminated
- Sponsor
- Roche
- Start
- May 2012
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of bevacizumab, paclitaxel in breast cancer, sponsored by Roche. Started May 2012; status: terminated.
02
Drugs
bevacizumabpaclitaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2011-005335-97.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005335-97.